

Petar Seferovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197774/publications.pdf>

Version: 2024-02-01

91
papers

5,130
citations

159585

30
h-index

98798

67
g-index

91
all docs

91
docs citations

91
times ranked

5259
citing authors

#	ARTICLE	IF	CITATIONS
1	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <i>Nature Reviews Cardiology</i> , 2021, 18, 169-193.	13.7	589
2	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	3.8	517
3	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
4	Epidemiology, pathophysiology and contemporary management of cardiogenic shock—A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1315-1341.	7.1	244
5	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	7.1	224
6	The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. <i>European Journal of Heart Failure</i> , 2019, 21, 402-424.	7.1	202
7	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardio-Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardio-Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	7.1	184
8	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 157-174.	7.1	181
9	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.1	170
10	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.1	144
11	Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e34-e61.	1.2	140
12	The <scp>Heart Failure Association Atlas</scp>: <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	7.1	130
13	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	7.1	128
14	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 854-871.	7.1	105
15	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	7.1	101
16	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
17	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	7.1	81
18	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1615-1633.	7.1	74

#	ARTICLE	IF	CITATIONS
19	<scp>ExtraHF</scp> survey: the first European survey on implementation of exercise training in heart failure patients. <i>European Journal of Heart Failure</i> , 2015, 17, 631-638.	7.1	69
20	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	7.1	69
21	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2021, 23, 1610-1632.	7.1	69
22	Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	7.1	67
23	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
24	Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 603-619.	7.1	57
25	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the ESC-HFA EORP Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	7.1	49
26	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	7.1	47
27	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2356-2362.	2.2	38
28	Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 191-198.	1.7	37
29	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	7.1	36
30	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
31	<scp>COVID-19</scp> vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.1	32
32	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	7.1	30
33	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. <i>Journal of Cardiac Failure</i> , 2021, 27, 727-743.	1.7	29
34	Cardiac remodelling—Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	7.1	29
35	Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 72-82.	1.8	27
36	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	3.8	27

#	ARTICLE	IF	CITATIONS
37	N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy. <i>Journal of Cardiology</i> , 2017, 70, 323-328.	1.9	25
38	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. <i>European Journal of Heart Failure</i> , 2020, 22, 763-774.	7.1	24
39	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. <i>Nutrients</i> , 2021, 13, 257.	4.1	24
40	Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. <i>European Journal of Heart Failure</i> , 2020, 22, 113-125.	7.1	23
41	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	3.1	23
42	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020, 22, 638-645.	7.1	23
43	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	7.1	23
44	Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. <i>International Journal of Cardiology</i> , 2017, 249, 191-197.	1.7	22
45	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1999-2007.	7.1	22
46	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	7.1	22
47	Percutaneous Therapy in Pericardial Diseases. <i>Cardiology Clinics</i> , 2017, 35, 567-588.	2.2	20
48	Glutathione Transferase P1 Polymorphism Might Be a Risk Determinant in Heart Failure. <i>Disease Markers</i> , 2019, 2019, 1-11.	1.3	20
49	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	7.1	20
50	Endothelial (Dys)Function in Lone Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2014, 21, 622-645.	1.9	20
51	Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 4030-4039.	2.2	19
52	Impaired endothelial function in lone atrial fibrillation. <i>Vojnosanitetski Pregled</i> , 2013, 70, 908-914.	0.2	18
53	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	1.7	18
54	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. <i>European Journal of Heart Failure</i> , 2022, 24, 916-926.	7.1	18

#	ARTICLE	IF	CITATIONS
55	Regional differences in exercise training implementation in heart failure: findings from the Exercise Training in Heart Failure (ExTraHF) survey. <i>European Journal of Heart Failure</i> , 2019, 21, 1142-1148.	7.1	14
56	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.2	14
57	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
58	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. <i>GeroScience</i> , 2021, 43, 2289-2304.	4.6	13
59	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. <i>Heart Failure Reviews</i> , 2020, 25, 85-91.	3.9	12
60	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	2.2	12
61	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021, 23, 1432-1436.	7.1	10
62	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	3.1	10
63	Oxidative stress and inflammation in heart failure: The best is yet to come. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 490-493.	1.8	10
64	Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation. <i>CardioRenal Medicine</i> , 2017, 7, 31-41.	1.9	8
65	Is left atrium the best kept secret of the heart? Left atrial dilatation and cardiovascular outcomes. <i>Heart</i> , 2019, 105, 1848-1849.	2.9	7
66	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	3.1	7
67	Heart failure with preserved ejection fraction in Asia: the far side of the moon?. <i>European Journal of Heart Failure</i> , 2019, 21, 37-39.	7.1	6
68	Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	7.1	6
69	Mitral valve endocarditis caused by <i>Pseudomonas aeruginosa</i> : a case report. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 676-679.	1.2	5
70	Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1931-1933.	1.8	5
71	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	3.1	5
72	ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management. <i>European Heart Journal</i> , 2021, 43, 11-13.	2.2	5

#	ARTICLE	IF	CITATIONS
73	Association between heart rate variability and haemodynamic response to exercise in chronic heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 77-82.	1.2	4
74	Age old problem: heart failure treatment in elderly. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1396-1398.	1.8	3
75	Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 739-742.	1.8	3
76	Vaccination in Heart Failure: An Approach to Improve Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 697-699.	0.6	2
77	A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1263-1267.	1.8	2
78	In search of a "safety zone"™ for glycaemic control: association between <scp>glycosylated haemoglobin</scp> levels and outcomes in patients with type 2 diabetes and cardiovascular disease. <i>European Journal of Heart Failure</i> , 2020, 22, 2035-2037.	7.1	2
79	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy " a call for action for referral and optimization of care. <i>Europace</i> , 2023, 25, .	1.7	2
80	Mitral valve endocarditis during brucellosis relapse. <i>Vojnosanitetski Pregled</i> , 2012, 69, 725-729.	0.2	1
81	Patients'™ knowledge and perspectives on vitamin K antagonists for stroke prevention in atrial fibrillation: implications for treatment quality. <i>Anatolian Journal of Cardiology</i> , 2017, 18, 239-240.	0.9	1
82	Adipokine profile as a novel screening method for cardiometabolic disease: Help or hindrance?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1543-1547.	1.8	1
83	Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply. <i>European Journal of Heart Failure</i> , 2021, 23, 197-198.	7.1	1
84	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. <i>Cardiac Failure Review</i> , 0, 8, .	3.0	1
85	Cutting the Gordian knot of left ventricular diastolic dysfunction: Role of opportunistic screening models. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1666-1669.	1.8	0
86	The eyes are the mirror of the heart: role of retinal microvascular abnormalities in predicting long-term risk of heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1216-1218.	7.1	0
87	Vaccination in Patients With Heart Disease. How Long Should We Wait? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 516.	0.6	0
88	Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1122-1124.	7.1	0
89	OUP accepted manuscript. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	0
90	Typical chest pain and precordial leads ST-elevation in patients with pacemakers - are we always looking at an acute myocardial infarction?. <i>Vojnosanitetski Pregled</i> , 2015, 72, 837-840.	0.2	0

#	ARTICLE	IF	CITATIONS
91	An ounce of prevention is worth a pound of cure: drugs and devices to prevent sudden cardiac death in heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 107-109.	1.8	0